Our Science

Despite significant progress over the past few decades in developing small molecule therapeutics against drug targets with clearly defined activation sites, the vast majority of potential drug targets in cancer do not fit this conventional model of drug discovery. Oncogenic targets that function as transcriptional drivers or through other protein-protein interactions are often partly disordered when isolated from binding partners or physiological complexes, generally lack obvious binding pockets, and may act through complex signaling pathways, complicating attempts to identify novel therapies through traditional screening methods or rational drug design. Despite a wealth of scientific target validation data, there is a critical need for new approaches to developing therapeutics against these targets, which include the most well-known oncogenes in some of the deadliest forms of cancer.

The foundation of Kronos Bio was built on over a decade of research into high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology. By combining small molecule microarrays (SMM) with extensive know-how in biological assay development, our technology platform enables high-throughput screens of chemical libraries against target proteins in a more physiologically relevant context. As a result, a single screening assay can identify compounds that bind or interfere with the target protein activity directly, disrupt protein-protein complexes, or affect nearest neighbor proteins that may indirectly modulate target activity. This approach is ideally suited for rapid discovery of unique ligands that can be utilized in the generation of novel modulators or degraders of historically challenging targets such as transcription factors.